Literature DB >> 12205639

A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease.

Miguel A Hernán1, Bahi Takkouche, Francisco Caamaño-Isorna, Juan J Gestal-Otero.   

Abstract

We conducted a systematic review to summarize the epidemiological evidence on the association between cigarette smoking, coffee drinking, and the risk of Parkinson's disease. Case-control and cohort studies that reported the relative risk of physician-confirmed Parkinson's disease by cigarette smoking or coffee drinking status were included. Study-specific log relative risks were weighted by the inverse of their variances to obtain a pooled relative risk and its 95% confidence interval (CI). Results for smoking were based on 44 case-control and 4 cohort studies, and for coffee 8 case-control and 5 cohort studies. Compared with never smokers, the relative risk of Parkinson's disease was 0.59 (95% CI, 0.54-0.63) for ever smokers, 0.80 (95% CI, 0.69-0.93) for past smokers, and 0.39 (95% CI, 0.32-0.47) for current smokers. The relative risk per 10 additional pack-years was 0.84 (95% CI, 0.81-0.88) in case-control studies and 0.78 (95% CI, 0.73-0.84) in cohort studies. Compared with non-coffee drinkers, relative risk of Parkinson's disease was 0.69 (95% CI, 0.59-0.80) for coffee drinkers. The relative risk per three additional cups of coffee per day was 0.75 (95% CI, 0.64-0.86) in case-control studies and 0.68 (95% CI, 0.46-1.00) in cohort studies. This meta-analysis shows that there is strong epidemiological evidence that smokers and coffee drinkers have a lower risk of Parkinson's disease. Further research is required on the biological mechanisms underlying this potentially protective effect.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12205639     DOI: 10.1002/ana.10277

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  242 in total

1.  Tobacco, coffee, and Parkinson's disease.

Authors:  Catharine Gale; Christopher Martyn; Chris Gale
Journal:  BMJ       Date:  2003-03-15

Review 2.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Malignant melanoma, breast cancer and other cancers in patients with Parkinson's disease.

Authors:  Kathrine Rugbjerg; Søren Friis; Christina Funch Lassen; Beate Ritz; Jørgen H Olsen
Journal:  Int J Cancer       Date:  2012-03-22       Impact factor: 7.396

4.  Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk.

Authors:  Iris Y Kim; Éilis J O'Reilly; Katherine C Hughes; Xiang Gao; Michael A Schwarzschild; Marjorie L McCullough; Marian T Hannan; Rebecca A Betensky; Alberto Ascherio
Journal:  Mov Disord       Date:  2018-01-10       Impact factor: 10.338

Review 5.  Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies.

Authors:  Mahyar Etminan; Bahi Takkouche; Francisco Caamaño Isorna; Ali Samii
Journal:  BMJ       Date:  2004-12-13

Review 6.  Inside-out neuropharmacology of nicotinic drugs.

Authors:  Brandon J Henderson; Henry A Lester
Journal:  Neuropharmacology       Date:  2015-02-04       Impact factor: 5.250

7.  Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease.

Authors:  R A Popat; S K Van Den Eeden; C M Tanner; F Kamel; D M Umbach; K Marder; R Mayeux; B Ritz; G W Ross; H Petrovitch; B Topol; V McGuire; S Costello; A D Manthripragada; A Southwick; R M Myers; L M Nelson
Journal:  Eur J Neurol       Date:  2011-01-31       Impact factor: 6.089

Review 8.  Oxidative damage to macromolecules in human Parkinson disease and the rotenone model.

Authors:  Laurie H Sanders; J Timothy Greenamyre
Journal:  Free Radic Biol Med       Date:  2013-01-15       Impact factor: 7.376

Review 9.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

10.  Nitric oxide synthase genes and their interactions with environmental factors in Parkinson's disease.

Authors:  Dana B Hancock; Eden R Martin; Jeffery M Vance; William K Scott
Journal:  Neurogenetics       Date:  2008-07-29       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.